JiangSu WuZhong Pharmaceutical Development is in trouble! A subsidiary has been sued for assisting in a tax fraud case and is also under investigation for violation of information disclosure regulations.

① JiangSu WuZhong Pharmaceutical Development announced that its subsidiary and the Chairman are being prosecuted for assisting in tax fraud of 0.242 billion yuan, and are also being investigated by the Securities Regulatory Commission for information disclosure violations, which may pose a risk of (Delisted); ② although the two incidents are closely timed, legal experts say that no correlation can be discerned at present; ③ since the third quarter of last year, JiangSu WuZhong's performance has shown significant improvement; ④ some investors have declared "they will protect their legitimate rights and interests" due to the significant fluctuations in stock prices.

cls.cnMar 7 10:07 ET

Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the

① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.

cls.cnMar 2 21:09 ET

JiangSu WuZhong Pharmaceutical Development is suspected of violations related to information disclosure and has been filed for investigation after years of losses, just turning a profit.|Brief Announcement

① JiangSu WuZhong Pharmaceutical Development has been put under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure laws; ② The company has reported a net income loss for six consecutive years, yet aims to turn a profit in 2024 by focusing on a single product in the medical aesthetics sector; ③ Previously, the company faced several instances of being penalized for various legal violations, but none have occurred in the last three years.

cls.cnFeb 26 09:00 ET

EHang and Anhui Jianghuai Automobile Group Corp.,Ltd. are collaborating to promote the construction of a low-altitude industrial park, with the low-altitude economy industry expected to accelerate its implementation.

① EHang, Anhui Jianghuai Automobile Group Corp.,Ltd. and Hefei Guoxian Holdings Co., Ltd. officially signed a global strategy cooperation agreement in Hefei. ② Currently, various regions across the country are introducing policy measures to support the development of the low-altitude economy, including the frequent introduction of bullish policies for the low-altitude economy and plans to use special bonds and ultra-long special treasury bonds and other financial tools to provide stable funding sources for the development of the low-altitude economy.

cls.cnFeb 25 19:13 ET

It was reported that FOSUN PHARMA will sell its Indian pharmaceutical company, and it stated that it will continue to promote the development of the Indian company in the Global market.

① It is rumored that FOSUN PHARMA will sell its pharmaceutical company Gland Pharma located in India, and the company stated it will continue to promote Gland Pharma's development and growth in the Global market. ② Previously, FOSUN PHARMA had reduced its Shareholding in Gland Pharma to supplement working capital, repay interest-bearing debts, and so on.

cls.cnFeb 20 18:46 ET

Huawei will release AI pathology models, and the Medical Industry is迎来 an important opportunity for intelligent upgrades.

① Huawei's data storage public account released information stating that it will launch the Ruijin pathological model based on the Huawei DCS AI solution. ② Jianghai Securities pointed out that under the guidance of the Health China 2030 Global Strategy, the Medical Industry is ushering in an important opportunity for intelligent upgrades.

cls.cnFeb 13 19:04 ET